Alphabiome AI
AI-Powered Microbiome Intelligence for Human Health
Company Overview
Snapshot
Founded in March 2022 by Yaniv Altshuler, Alphabiome AI operates with 1–10 employees. The company has raised $8,000,000 across four funding rounds from three investors. In May 2025, Alphabiome AI secured seed funding, with.
Business overview
Alphabiome AI leverages artificial intelligence to analyze the genetic complexities of the human microbiome. The company's core technology decodes microbial DNA to identify biomarkers that predict treatment efficacy, aiming to transform disease understanding, diagnosis, and treatment. Alphabiome AI serves markets in North America, Europe, and Oceania, focusing on drug development, clinical decision-making, and precision medicine within the Health Tech & Life Sciences sector.
Strategic signal
Alphabiome AI's seed funding in May 2025, with AIX Ventures as a lead investor, signals strong investor confidence in its AI-powered microbiome intelligence platform. This capital infusion is crucial for advancing its proprietary technology, which converts genetic fragments into actionable insights for drug development and precision medicine, indicating a clear trajectory towards further innovation and market penetration in the health tech and life sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Alphabiome AI's core mission?
- Alphabiome AI's mission is to unlock the full potential of the microbiome to transform how diseases are understood, diagnosed, and treated by using artificial intelligence to decode genetic complexity and identify biomarkers.
- When was Alphabiome AI founded?
- Alphabiome AI was founded in March 2022.
- Which investor led Alphabiome AI's seed funding round in May 2025?
- AIX Ventures participated as a lead investor in Alphabiome AI's seed funding round in May 2025.
- What is Alphabiome AI's primary technology?
- Alphabiome AI's proprietary technology enables large-scale, reference-free analysis of microbial DNA, converting genetic fragments into actionable insights for drug development, clinical decision-making, and precision medicine.